Study S001021

A Randomized, Open-label, Cross-over Study to Evaluate Patient Preferences for Eucreas® Versus Victoza® as add-on to Metformin in Type 2 Diabetes Mellitus Patients Who Did Not Have Adequate Glycaemic Control With Metformin.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01518101
Acronym: PREFER
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 62
Start: 2012-01
Primary completion: 2012-10
Lead sponsor: Novartis Pharmaceuticals
Conditions: Type 2 Diabetes
Interventions: DRUG:Vildagliptin/ Metformin; DRUG:Liraglutide; DRUG:Metformin
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2011-003818-16

Registered primary outcomes

Proportion of patients preferring each treatment regimen [At week 24]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020535	Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study. Lüdemann J, Therapeutic advances in endocrinology and metabolism	2015	Randomized trial	PMID 26301063 DOI	registry reference RESULT:26301063